Objectives: Pulmonary Mycobacterium avium complex (MAC) prevalence is on the rise worldwide. The average therapy duration is 1.5 years, which is associated with poor cure rates. Our objective was to develop a programme to design a combination therapy regimen for pulmonary MAC to be administered for 6 months or less with efficacy in .90% of patients.
The problem of pulmonary Mycobacterium avium-intracellulare complex Mycobacterium avium complex (MAC) most commonly causes chronic pulmonary disease. [1] [2] [3] In recent large studies, e.g. in Oregon, USA, the disease incidence was 4.2 per 100000 in 2007 and 4.8 per 100000 in 2012; the incidence increased 5-fold in people older than 70 years. 4, 5 This is higher than the US tuberculosis incidence of 3.0 per 100000 in 2014. In the UK, the incidence of pulmonary MAC between 2007 and 2012 increased from 1.3 to 2.2 per 100000. 6 In Australia, the incidence rose from 2.2 per 100000 in 1999 to 3.2 per 100000 people in 2005. 7 Thus the incidence of disease has been rising, not just in the USA, but also in other parts of the world.
In terms of pathology, MAC is an intracellular pathogen, which is taken up by alveolar macrophages and proliferates within vacuoles in the cytoplasm; it is encountered in macrophages in pulmonary lesions. 8 Clinically, pulmonary MAC disease manifests as one of three major syndromes. The first syndrome is encountered mainly in men in their late 40s and early 50s who have a history of lung damage from smoking and alcohol, and present with fibrocavitary disease in the apical or upper lobe of the lung. 9, 10 Left untreated, this progresses within 1-2 years to extensive cavitation and destruction of lung tissue and/or respiratory failure. 9, 10 The second syndrome is encountered in women in their 50s, usually of European descent, who have no history of underlying lung disease or smoking: they present with nodular bronchiectatic disease most often in the right middle lobe or lingula of the lung. [11] [12] [13] Although this form of disease tends to have a much slower progression, respiratory failure can occur. 13 The third syndrome is encountered in young patients with cystic fibrosis who have bronchiectasis; 14, 15 these patients often have mixed infections, the treatment of which can be challenging due the rapid clearance of many antibiotics in young people. 
Current therapy and its response rates
The currently recommended treatment for pulmonary MAC is a combination of either clarithromycin or azithromycin with ethambutol and a rifamycin, often rifabutin. 17 Response rates of 55%-65% have been reported for this regimen based on noncomparative, non-controlled, single-centre studies. 18 We recently performed a systematic review and meta-analysis of sputum conversion rates, based on intent-to-treat analyses. 19 Patients received therapy for an average of 18 months with macrolidebased regimens and 23 months with macrolide-free regimens and achieved sputum conversion rates of 53% and 32% at the 6 month time point, respectively, but of only 22% for therapy duration longer than 1 year. 19 Thus response rates can, at best, be described as poor if earlier timepoints are used, and are woeful for treatment duration longer than 1 year, which is the norm. Given these findings, we sought a more systematic approach to identify other antibiotics and combinations that could be more efficacious than current standard therapy.
Literature search for pharmacokinetics/ pharmacodynamics (PK/PD) studies
We performed a literature search based on the following MeSH headings 'Mycobacterium avium' AND 'pharmacokinetics/pharmacodynamics' in PubMed, with no limitation by dates or by language, with last access on 22 November 2016. The search revealed three papers, two from our prior work, and one that was a pharmacokinetic paper with no pharmacodynamics. [20] [21] [22] We augmented the search with work in the current JAC Supplement, which therefore represents the most extensive antimicrobial PK/PD work and review done for pulmonary MAC to date. These included work with oxazolidinones, 8-methoxyquinolones, rifamycins, b-lactam/b-lactamase pairs, macrolides, phenothiazines and ethambutol. 20, [23] [24] [25] [26] [27] [28] [29] [30] The relationship between drug exposure and total microbial burden is often modelled using the inhibitory sigmoid maximum kill (E max ) relationship, as shown in the example of linezolid in Figure 1 . The model parameters are: (i) microbial burden (cfu/mL) with no treatment (controls) or E con ; (ii) maximal microbial kill (E max ) in cfu/mL (i.e. efficacy); (iii) drug exposure mediating 50% of E max or EC 50 (i.e. the potency, where EC is the effective concentration); and (iv) the Hill slope:
This relationship is used to identify optimal exposure, defined as the exposure mediating 80% of E max (EC 80 ). In order to investigate the possibility of shortening therapy for pulmonary MAC, we are also interested in other targets in addition to EC 80 , including the exposure that just holds bacterial burden constant compared with day 0 (i.e. stasis) which is common with currently recommended agents, and achieving kills of 1.0 log 10 cfu/mL below stasis (bactericidal) and 2.0 log 10 cfu/mL below stasis. For acquired drug resistance, the relationship between exposure and the drug-resistant subpopulation is described by a system of U-shaped curves. 31, 32 Based on our literature search, we identified the E max , EC 80 , exposure associated with bacteriostasis, 1.0 log 10 cfu/mL kill and 2.0 log 10 cfu/mL kill, shown in Table 1 . These results were all based on experiments in the hollow-fibre system model of pulmonary MAC (HFS-MAC); no data for these indices have been generated using any other types of preclinical models. A similar HFS model of pulmonary tuberculosis was recently shown to have a predictive accuracy of 94% compared with clinical events, and to correlate closely with clinical events. 33, 34 Both models were designed to allow extensive exposure-effect studies, dose fractionation studies and the ranking of different microbial kill rates by combination therapy regimens. However, the predictive accuracy of the HFS-MAC is yet to be established. As can be seen in Table 1 , the ethambutol E max was ,1.0 log 10 cfu/mL and even at maximal effect the drug failed to lower the bacterial burden below that level on day 0. 27 In comparison, azithromycin, achieved a maximal kill of 2.11 log 10 cfu/mL, however its kill below stasis was only 0.6 log 10 cfu/mL. 29 Thus, azithromycin and ethambutol, which constitute the backbone of current treatment regimens, lower bacterial burden below starting inoculum only minimally. On the other hand, the E max of oxazolidinones such as linezolid and tedizolid as monotherapy, as well as that of thioridazine, exceeds that of azithromycin and ethambutol, with .1.0 log 10 cfu/mL kill below stasis. 23, 24, 28 Similarly the microbial kill by ceftazidime/avibactam below the day 0 bacterial burden was better than by azithromycin or ethambutol. 25 These kill rates suggest that these other agents could form a good backbone that would allow rapid microbial kill, subject to the drugs being well tolerated by pulmonary MAC patients. Other potential anti-MAC drugs such as clofazimine and bedaquiline are yet to be studied in this model Table 2 shows the slopes for maximal kill in experimental combination therapy regimens, which have not yet been PK/PD optimized, in the HFS-MAC. The standard therapy regimen of ethambutol, azithromycin and rifabutin fails after 14 days. Using the experimental four-drug combination regimen of ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM), the kill rate slope was 30% steeper than with standard therapy, with a time to failure of 21 days. It is conceivable that if the CARTM regimen is further optimized, total sterilization of the systems could be achieved. Using PK/PD to build a short-course chemotherapy regimen
The pharmacometric lessons from the literature include the ability to identify exposures likely to achieve the highest amount of kill, identifying the fastest kill rates mediated by a combination of drugs, and their exposures. These exposures are the crucial link to translating the findings to the clinic. In the case of tuberculosis, this approach has now become standard. [34] [35] [36] [37] [38] In addition, this has also been tried for more intractable pulmonary pathogens, such as Mycobacterium abscessus. [39] [40] [41] [42] We used all these lessons to identify steps to be used in designing a short-course chemotherapy regimen for pulmonary MAC.
Step 1: Rapid screen to identify drugs with activity against MAC There are several mycobacteriology and pharmacology assumptions that will have to be abandoned in the pursuit of shorter-duration regimens for pulmonary MAC. As an example, the standard teaching has been that Mycobacterium spp. are naturally resistant to most b-lactam antibiotics due to production of b-lactamases, reduced affinity of drug targets and limited permeability of the cell wall. [43] [44] [45] Our finding that ceftazidime, with supposedly poor antiGram-positive activity, can be highly effective against MAC when combined with avibactam prompted us to set up a deliberate de novo search for drugs through all antimicrobial pharmacological classes without bias or assumptions. 25 We propose that all antibiotic pharmacophores be screened for activity against MAC in microbroth and macrobroth assays. Use of optical density, LIVE-DEAD assays, Mycobacterial Growth Indicator Tube (MGIT) time to positivity tests, with a backup of cfu/mL, and 7 day co-incubation with drug give a relatively rapid throughput screening method. Drugs that are promising based on both E max and concentrations that could be clinically achievable are then tested in 24-well plates of MAC-infected and activated macrophage cell lines in RPMI 1640 medium with 10% FBS. Drugs that pass this stage are then advanced to the MIC testing stage, whereby a large enough number of clinical isolates are tested to identify MICs that would be encountered in the clinic.
Step 2: Setting exposure targets for efficacy in the HFS-MAC HFS-MAC are used to identify the following: (i) inhibitory sigmoid E max relationship based on pharmacokinetics of drugs actually achieved in the lungs of patients, (ii) exposure associated with suppression of resistance and (iii) the PK/PD index associated with optimal microbial kill. The first output gives us a way to identify the EC 80 and such exposures as those associated with !1.0 log 10 cfu/mL kill, the second output gives the exposure associated with resistance suppression, while the third provides the scientific rationale on the best dosing schedule for treatment of pulmonary MAC disease. The best dosing schedule should never be set simply based on half-life of the drug, but must be deliberately identified in dose-fractionation studies. This allows identification of the PK/PD index associated with optimal effect or resistance suppression: either peak to MIC ratio (C max /MIC), or Step 3: a PK/PD approach for combination therapy
Combination therapy is administered for pulmonary MAC in order to achieve higher rates of microbial kill than with monotherapy, and in order to abrogate the emergence of acquired drug resistance to monotherapy which is common in all mycobacteria. 29 Therefore, once the PK/PD relationships for monotherapy have been identified, there is need for a deliberate approach to combine two or more antibiotics in a manner that is most advantageous to killing the bacteria. The first consideration is on the criteria used to choose drugs that go into the combination. This requires knowledge of the mechanism of action of the antibiotic. We avoid combining drugs in the same pharmacophore and drugs with the same mechanism of effect. We also avoid drugs with overlapping toxicities, or those that have synergistic toxicities.
Once the drugs to be combined have been chosen, then the exposures likely to lead to synergy or additivity are chosen based on experimental observations. A key finding from combination therapy studies in children with tuberculosis, in which the Mycobacterium tuberculosis is predominantly intracellular, as well as pulmonary tuberculosis in adults, was that concentrationdependent synergy and antagonism are extremely common. [46] [47] [48] [49] [50] [51] [52] Therefore, the same pair or triple set of drugs can be antagonistic or synergistic or additive, depending on the concentrations examined. It is therefore crucial to select doses that go into a drug combination that will result in concentrations that are at the very least not antagonistic, if not synergistic. Moreover, some drugs are likely to be more toxic when used in combination than as single agents. This implies that several concentrations or exposures of the drugs with activity against MAC being considered for a combination regimen will have to be examined. However, since up to 49 hollowfibre systems (147 HFS-MAC in triplicate) would be needed to be able to examine the whole exposure-response surface for the interaction of, say, seven concentrations per drug, costs would be prohibitive. We propose an intermediate rapid throughput step for this, using 24-well plates, similar to the ones we employed for moxifloxacin and thioridazine as described elsewhere in this Supplement. 30 Each of seven different exposures of drug A are coincubated with each of seven different concentrations of drug B in a matrix of 49 wells that contain MAC-infected adherent humanderived macrophages, a '7%7' matrix, in triplicate (149 wells). Concentrations are chosen based on results of monotherapy in step 1. Since we are interested in rapid kill, we co-incubate for only 7 days, and then examine for both cytotoxicity and bacterial burden. The pharmacodynamic effect of the antibiotic interaction is then calculated based on either Bliss independence or the Greco model. 53, 54 With this approach, an interaction factor a is calculated, with 95% CI. An a value with a 95% CI that is greater than zero indicates synergy, an a value with a 95% CI that spans zero means that there is additivity of effect, and an a value with the upper 95% CI less than zero means that there is antagonism. Exposures that are either synergistic or additive are then chosen, and advanced to the HFS-MAC. 46 The same analysis will be applied to cytotoxicity, in order to minimize toxicity.
In the HFS-MAC, regimens chosen based on additivity or synergy against MAC in 24-well plates are administered and compared with non-treated controls (negative controls) and to the standard regimen of macrolide/ethambutol/rifabutin, in triplicate HFS-MAC. The experimental regimen is administered with a dosing schedule linked to the PK/PD index. An example of such a regimen design is the moxifloxacin/thioridazine combination study we described earlier. 30 In these studies, the time-kill slopes are compared with those of the standard regimen, with the aim of identifying an experimental dual-therapy regimen that has a slope !2-fold steeper than (and outside the 95% CI of) the standard therapy regimen. A second criterion is that such a regimen should also suppress acquired drug resistance. After such a regimen is identified, the next step is another HFS-MAC study in which either the 0, EC 20 , EC 50 , EC 80 or EC 90 of a third drug is added to the dualtherapy regimen that killed twice as fast as the standard regimen, using the same positive and negative controls as in the dual-therapy regimen study. First, the slopes will be compared with those for standard combination therapy, to try to identify a regimen that is at least four times faster than current 18 month regimen. Second, we also want identify a regimen that, unlike the standard regimen, entirely sterilizes the HFS-MAC. Third, we also want to identify a regimen that suppresses the emergence of resistance.
Step 4: Use of Monte Carlo simulations to translate results to the clinic In all patients, there exists significant between-patient pharmacokinetic variability for any drug administered, and often betweenoccasion variability. This means that when patients are treated with the same dose (even in mg/kg) they will achieve different concentration-time profiles. Thus, in designing an optimally dosed regimen for pulmonary MAC, this variability will need to be accounted for. Table 3 summarizes the population pharmacokinetic parameters of the drugs for which PK/PD work has been performed for pulmonary MAC, based on the literature. [55] [56] [57] [58] [59] Since pulmonary MAC is by definition a lung disease, the penetration ratios of drug into epithelial lining fluid (ELF) and alveolar macrophages will be important to quantify; these are also shown in Table 3 for some of the different drugs.
Monte Carlo simulations take this pharmacokinetic variability into account, with implementation steps that have been described in various publications. 37, 60, 61 The main experiment is simple: given a dose and the population variability, what proportion of patients will achieve the target exposure in the lung? The target exposure can be the EC 80 or 1.0 log 10 cfu/mL kill or the exposure associated with synergy for a pair of drugs. Essentially for every dose, the pharmacokinetic parameter estimates and their covariance matrix are used as the domain of input in Monte Carlo experiments to generate a distribution of pharmacokinetic parameters such as C max s, concentration-time profiles or AUC 0-24 for 10000 individuals. We use 10000 in silico patients because that sample size stabilizes the tail of the variance. Next, since the MICs of clinical MAC isolates are a distribution, with MICs varying from patient to patient, the drug exposure at each MIC within the distribution is calculated, and the results summated by calculating the cumulative fraction of response over the entire MIC distribution.
Short-course therapy programme for pulmonary MAC
The experiment is repeated with increasing doses. Achievement of the target exposure in .90% of the 10000 patients marks the end of the dose-ranging Monte Carlo experiments; the lowest dose achieving the cumulative fraction of response .90% is chosen as the optimal dose for clinical use in the combination regimen. As an example, Monte Carlo simulations for the bactericidal effect target (1.0 log 10 cfu/mL kill or EC 80 ) for tedizolid treatment of pulmonary MAC revealed that the cumulative fraction of response was .90% with the standard dose of 200 mg/day. 24 In the cases where the target concentration exposure for toxicity are known, findings from the same experiments can be used to find a dose that minimizes toxicity. This exercise is repeated for each drug in the combination regimen.
Conclusions
Drug concentrations and exposures are key determinants of bacterial response to antimicrobial agents. Here we outline a systematic programme to identify target exposures related to optimal microbial kill of pulmonary MAC for one-, two-, three-and fourdrug combination therapy. Target exposures obtained via this approach can then be translated to optimal doses using Monte Carlo simulations for testing in clinical trials.
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